AR036856A2 - Clorhidrato de paroxetina anhidro, y procedimiento para su preparacion - Google Patents
Clorhidrato de paroxetina anhidro, y procedimiento para su preparacionInfo
- Publication number
- AR036856A2 AR036856A2 ARP020103931A ARP020103931A AR036856A2 AR 036856 A2 AR036856 A2 AR 036856A2 AR P020103931 A ARP020103931 A AR P020103931A AR P020103931 A ARP020103931 A AR P020103931A AR 036856 A2 AR036856 A2 AR 036856A2
- Authority
- AR
- Argentina
- Prior art keywords
- characteristic peaks
- paroxetine hydrochloride
- hydrochloride anhydrous
- shows
- theta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formas B, C y D de anhidro de clorhidrato de paroxetina que pueden ser utilizadas para tratar y prevenir desórdenes médicos, tales como depresión, desorden compulsivo obsesivo y pánico. El anhidro de clorhidrato de paroxetina en Forma B tiene un punto de fusión de alrededor de 138°C; bandas significativas IR a alrededor de 538, 574, 614, 675, 722, 762, 782, 815, 833, 884, 925, 938, 970, 986, 1006, 1039, 1069, 1094, 1114, 1142, 1182, 1230, 1274, 1304, 1488, 1510, 1574, 1604, 1631 cm-1; la endoterma de DSC, medida a 10°C por minuto muestra un máximo a aproximadamente 137°C en ambos un bol abierto y un bol cerrado; muestra también un difractograma de rayos X que incluye picos característicos a 5,7, 11,3, 12,4, 14,3 grados 2 theta y un espectro RMN de estado sólido que incluye los picos característicos a 154,6, 148,3, 150,1, 141,7, 142,7, 139,0 ppm. El anhidro de clorhidrato de paroxetina en Forma C tiene un punto de fusión de alrededor de 164°C, bandas significativas IR a alrededor de 540, 574, 615, 674, 720, 760, 779, 802, 829, 840, 886, 935, 965, 984, 1007, 1034, 1092, 1109, 1139, 1183, 1218, 1240, 1263, 1280, 1507, 1540, 1558, 1598, 1652 cm-1; la endoterma de DSC, medida a 10°C por minuto muestra un máximo a aproximadamente 161°C en ambos un bol abierto y un bol cerrado; muestra también un difractograma de rayos X que incluye picos característicos a 10,1, 12,1, 13,1, 14,3 grados 2 theta y un espectro RMN de estado sólido que incluye los picos característicos a 154,0, 148,5, 143,03, 140,4 ppm. El anhidro de clorhidrato de paroxetina en Forma D existe como un sólido semi-cristalino con un punto de fusión de alrededor de 125°C con características físicas similares a cuando es preparado a partir de un solvato precursor de tolueno, teniendo dicho solvato precursor de tolueno bandas significativas IR a alrededor de 1631, 1603, 1555, 1513, 1503, 1489, 1340, 1275, 1240, 1221, 1185, 1168, 1140, 1113, 1101, 1076, 1037, 1007, 986, 968, 935, 924, 885, 841, 818, 783, 760, 742, 720, 698, 672, 612, 572, 537 y 465 cm-1; y picos característicos de difracción de rayos X a 7,2, 9,3, 12,7, y 14,3 grados 2 theta. Se describe un procedimiento de preparación de anhidro de clorhidrato de paroxetina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9502297.6A GB9502297D0 (en) | 1995-02-06 | 1995-02-06 | Novel compound |
GBGB9503112.6A GB9503112D0 (en) | 1995-02-17 | 1995-02-17 | Novel compound |
GBGB9509807.5A GB9509807D0 (en) | 1995-05-15 | 1995-05-15 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR036856A2 true AR036856A2 (es) | 2004-10-06 |
Family
ID=27267578
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960101230A AR001982A1 (es) | 1995-02-06 | 1996-02-01 | Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion |
ARP020103931A AR036856A2 (es) | 1995-02-06 | 2002-10-18 | Clorhidrato de paroxetina anhidro, y procedimiento para su preparacion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960101230A AR001982A1 (es) | 1995-02-06 | 1996-02-01 | Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion |
Country Status (47)
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3882224B2 (ja) | 1996-05-31 | 2007-02-14 | 旭硝子株式会社 | パロキセチンの製造方法 |
EP1384720A1 (en) * | 1996-06-13 | 2004-01-28 | SUMIKA FINE CHEMICALS Co., Ltd. | Process for drying paroxetine hydrochloride |
JP2000514653A (ja) * | 1996-07-15 | 2000-11-07 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 立体特異的分割のためのエステラーゼのスクリーニングおよびその使用 |
US6638948B1 (en) | 1996-09-09 | 2003-10-28 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
US5672612A (en) * | 1996-09-09 | 1997-09-30 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
CA2193939C (en) * | 1996-12-24 | 2002-02-12 | K.S. Keshava Murthy | Useful form of anhydrous paroxetine hydrochloride |
ES2155995T3 (es) * | 1997-06-10 | 2001-06-01 | Synthon Bv | Compuestos de 4-fenilpiperidina. |
EP0903345B1 (de) * | 1997-08-08 | 2000-10-04 | Aventis Pharma Deutschland GmbH | Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid |
GB9726907D0 (en) * | 1997-12-19 | 1998-02-18 | Smithkline Beecham Plc | Novel compounds |
SK13622000A3 (sk) * | 1998-03-16 | 2001-03-12 | Smithkline Beecham Plc | Kryštalická forma paroxetínu, farmaceutický prostriedok a použitie |
AU2003200534B2 (en) * | 1998-03-24 | 2004-12-02 | Smithkline Beecham Plc | Paroxetine compositions |
US6699882B2 (en) | 1998-03-24 | 2004-03-02 | Smithkline Beecham P.L.C. | Paroxetine compositions |
GB9806312D0 (en) * | 1998-03-24 | 1998-05-20 | Smithkline Beecham Plc | Novel formulations |
JP3796351B2 (ja) | 1998-04-13 | 2006-07-12 | 住友化学株式会社 | パロキセチン塩酸塩無水和物の乾燥方法 |
GB9812941D0 (en) * | 1998-06-16 | 1998-08-12 | Smithkline Beecham Plc | Method of treatment |
CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
ES2138937B1 (es) | 1998-07-07 | 2000-10-01 | Medichem Sa | Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen. |
ID27914A (id) * | 1998-08-07 | 2001-05-03 | Smithkline Beecham Plc | Proses untuk penyiapan bentuk anhidrat paroksetina hidroklorida bukan kristal |
GB9824298D0 (en) * | 1998-11-05 | 1998-12-30 | Smithkline Beecham Plc | Novel process |
GB9826175D0 (en) * | 1998-11-28 | 1999-01-20 | Smithkline Beecham Plc | Novel process |
GB9826176D0 (en) * | 1998-11-28 | 1999-01-20 | Smithkline Beecham Plc | Novel process |
GB9826178D0 (en) * | 1998-11-30 | 1999-01-20 | Smithkline Beecham Plc | Novel process |
DE69913377T2 (de) * | 1998-11-30 | 2004-12-30 | Smithkline Beecham P.L.C., Brentford | Gemischte Paroxetin-Propan-2-ol-Solvate |
GB9826171D0 (en) * | 1998-11-30 | 1999-01-20 | Smithkline Beecham Plc | Novel compounds |
GB9826180D0 (en) * | 1998-11-30 | 1999-01-20 | Smithkline Beecham Plc | Novel process |
GB9826242D0 (en) * | 1998-11-30 | 1999-01-20 | Smithkline Beecham Plc | Novel process |
GB9828767D0 (en) * | 1998-12-29 | 1999-02-17 | Smithkline Beecham Plc | Novel process |
ATE311883T1 (de) * | 1999-03-12 | 2005-12-15 | Aesica Pharmaceuticals Ltd | Stabile pharmazeutische anwendungsform für paroxetin-anhydrat |
GB9914583D0 (en) * | 1999-06-22 | 1999-08-25 | Smithkline Beecham Plc | Novel process |
GB9914585D0 (en) * | 1999-06-22 | 1999-08-25 | Smithkline Beecham Plc | Novel process |
GB9919001D0 (en) * | 1999-08-12 | 1999-10-13 | Smithkline Beecham Plc | Novel process |
GB9923446D0 (en) * | 1999-10-04 | 1999-12-08 | Smithkline Beecham Plc | Novel process |
GB9923445D0 (en) * | 1999-10-04 | 1999-12-08 | Smithkline Beecham Plc | Novel process |
GB9923439D0 (en) * | 1999-10-04 | 1999-12-08 | Smithkline Beecham Plc | Novel process |
HU226912B1 (en) * | 2000-04-07 | 2010-03-01 | Richter Gedeon Nyrt | New paroxetin salt and medicament containing it |
AU2001286232A1 (en) * | 2000-09-14 | 2002-03-26 | Asahi Glass Company, Limited | Process for producing paroxetine salt containing substantially no organic solvent |
AU2002259114A1 (en) * | 2002-02-22 | 2003-09-09 | Teva Pharmaceutical Industries Ltd. | Preparation of paroxetine involving novel intermediates |
WO2007062147A1 (en) * | 2005-11-22 | 2007-05-31 | Teva Pharmaceutical Industries Ltd. | Crystal forms of cinacalcet hci and processes for their preparation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
DE3688827T2 (de) * | 1985-10-25 | 1994-03-31 | Beecham Group Plc | Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel. |
GB8626936D0 (en) * | 1986-11-11 | 1986-12-10 | Ferrosan As | Treatment |
DK715988D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Etherifikation og dealkylering af piperidin-derivater samt intermediater |
DK716088D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Reduktion af piperidin-dion-derivater samt intermediat |
EP0558679A1 (en) * | 1990-11-24 | 1993-09-08 | BEECHAM GROUP plc | Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia |
GB9325644D0 (en) * | 1993-12-15 | 1994-02-16 | Smithkline Beecham Plc | Novel formulation |
-
1996
- 1996-02-01 SK SK143-96A patent/SK283608B6/sk not_active IP Right Cessation
- 1996-02-01 AR ARP960101230A patent/AR001982A1/es not_active Application Discontinuation
- 1996-02-02 RO RO96-00183A patent/RO112426B1/ro unknown
- 1996-02-02 IE IE960104A patent/IE80500B1/en not_active IP Right Cessation
- 1996-02-02 EP EP96903970A patent/EP0808314B1/en not_active Expired - Lifetime
- 1996-02-02 DE DE19603797A patent/DE19603797C2/de not_active Revoked
- 1996-02-02 BR BR9600534A patent/BR9600534A/pt not_active IP Right Cessation
- 1996-02-02 MC MC2329A patent/MC2411A1/xx unknown
- 1996-02-02 AU AU43328/96A patent/AU701518C/en not_active Ceased
- 1996-02-02 EP EP03078024A patent/EP1378508A1/en not_active Withdrawn
- 1996-02-02 DE DE1996631298 patent/DE69631298T2/de not_active Expired - Lifetime
- 1996-02-02 WO PCT/EP1996/000447 patent/WO1996024595A1/en active IP Right Grant
- 1996-02-02 MY MYPI96000383A patent/MY132529A/en unknown
- 1996-02-02 LV LVP-96-31A patent/LV11618B/en unknown
- 1996-02-02 AU AU47864/96A patent/AU4786496A/en not_active Abandoned
- 1996-02-02 CZ CZ0032096A patent/CZ297171B6/cs not_active IP Right Cessation
- 1996-02-02 EP EP01115079A patent/EP1136490B1/en not_active Expired - Lifetime
- 1996-02-02 FR FR9601297A patent/FR2730232B1/fr not_active Expired - Fee Related
- 1996-02-02 MX MX9600484A patent/MX9600484A/es not_active IP Right Cessation
- 1996-02-02 DE DE69621777T patent/DE69621777T2/de not_active Expired - Lifetime
- 1996-02-03 SG SG1996000861A patent/SG43787A1/en unknown
- 1996-02-03 KR KR1019960002620A patent/KR100289885B1/ko not_active IP Right Cessation
- 1996-02-04 DZ DZ960030A patent/DZ1989A1/fr active
- 1996-02-05 TW TW085101374A patent/TW503238B/zh not_active IP Right Cessation
- 1996-02-05 SE SE9600406A patent/SE521084C2/sv not_active IP Right Cessation
- 1996-02-05 IT IT96MI000203A patent/IT1289532B1/it active IP Right Grant
- 1996-02-05 PL PL96312646A patent/PL189247B1/pl unknown
- 1996-02-05 UA UA96020442A patent/UA49796C2/uk unknown
- 1996-02-05 SI SI9600378A patent/SI21923B/sl not_active IP Right Cessation
- 1996-02-05 IL IL11703596A patent/IL117035A/xx unknown
- 1996-02-05 CA CA002210023A patent/CA2210023C/en not_active Expired - Fee Related
- 1996-02-05 CA CA002168829A patent/CA2168829C/en not_active Expired - Fee Related
- 1996-02-05 BG BG100333A patent/BG62967B1/bg unknown
- 1996-02-05 LU LU88711A patent/LU88711A1/fr unknown
- 1996-02-05 CN CN96103526A patent/CN1090187C/zh not_active Expired - Fee Related
- 1996-02-05 NO NO960472A patent/NO301009B1/no not_active IP Right Cessation
- 1996-02-05 NZ NZ280943A patent/NZ280943A/en not_active IP Right Cessation
- 1996-02-05 ES ES09600262A patent/ES2114471B1/es not_active Expired - Fee Related
- 1996-02-05 JP JP8018679A patent/JP2915338B2/ja not_active Expired - Fee Related
- 1996-02-05 CA CA002211522A patent/CA2211522C/en not_active Expired - Fee Related
- 1996-02-05 MA MA24157A patent/MA23802A1/fr unknown
- 1996-02-05 NL NL1002248A patent/NL1002248C2/xx not_active IP Right Cessation
- 1996-02-05 HU HU9600255A patent/HUP9600255A1/hu unknown
- 1996-02-05 GR GR960100038A patent/GR1002466B/el not_active IP Right Cessation
- 1996-02-05 RU RU96102180A patent/RU2125052C1/ru not_active IP Right Cessation
- 1996-02-05 AT AT0021096A patent/AT407528B/de not_active IP Right Cessation
- 1996-02-05 FI FI960519A patent/FI111544B/fi not_active IP Right Cessation
- 1996-02-05 CN CNB2004100855519A patent/CN1289496C/zh not_active Expired - Fee Related
- 1996-02-05 DK DK011996A patent/DK11996A/da not_active Application Discontinuation
- 1996-02-05 CA CA002210022A patent/CA2210022C/en not_active Expired - Fee Related
- 1996-02-05 BE BE9600101A patent/BE1009112A3/fr not_active IP Right Cessation
- 1996-02-05 SI SI9600036A patent/SI9600036B/sl not_active IP Right Cessation
- 1996-02-06 CH CH00304/96A patent/CH688353A5/de not_active IP Right Cessation
- 1996-02-06 TR TR96/00096A patent/TR199600096A2/xx unknown
- 1996-02-06 CH CH01510/97A patent/CH689229A5/de not_active IP Right Cessation
- 1996-02-06 OA OA60773A patent/OA10261A/en unknown
- 1996-02-06 CH CH02051/98A patent/CH689804A5/de not_active IP Right Cessation
- 1996-02-06 PT PT101827A patent/PT101827B/pt not_active IP Right Cessation
-
1997
- 1997-02-28 NO NO19970939A patent/NO311519B1/no not_active IP Right Cessation
- 1997-05-08 HK HK59397A patent/HK59397A/xx not_active IP Right Cessation
-
1998
- 1998-12-02 JP JP10342812A patent/JPH11228571A/ja active Pending
-
2000
- 2000-08-31 CN CN001268872A patent/CN1216055C/zh not_active Expired - Fee Related
-
2001
- 2001-02-12 DK DKPA200100223 patent/DK200100223A/da not_active Application Discontinuation
- 2001-10-18 NO NO20015070A patent/NO20015070D0/no not_active Application Discontinuation
-
2002
- 2002-10-18 AR ARP020103931A patent/AR036856A2/es unknown
-
2003
- 2003-02-03 FI FI20030162A patent/FI20030162A/fi unknown
- 2003-03-12 FI FI20030370A patent/FI20030370A/fi not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR036856A2 (es) | Clorhidrato de paroxetina anhidro, y procedimiento para su preparacion | |
TW200628152A (en) | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorsers | |
PA8493701A1 (es) | Compuestos para tratar la obesidad | |
WO2002074758A3 (en) | Novel amines as histamine-3 receptor ligands and their therapeutic applications | |
MXPA01007968A (es) | Compuestos derivados del felbamato. | |
DE60024588D1 (de) | Substituierte porphyrine und deren therapeutische verwendungen | |
WO2003089434A3 (en) | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF | |
EP1759701A3 (en) | Buproprion Metabolites and Methods of Their Synthesis and Use. | |
ES2117090T3 (es) | Procedimiento para obtener formas granulares de aditivos para polimeros organicos. | |
UA66825C2 (uk) | Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності | |
DE69414554D1 (de) | Heterocyclische verbindungen und ihre herstellung und verwendung | |
UY28815A1 (es) | Agentes terapéuticos | |
CA2353133A1 (en) | Treatment of disorders secondary to organic impairments | |
ATE475640T1 (de) | Antagonisten des opioidrezeptors | |
GB9923077D0 (en) | Sapogenin derivatives and their use | |
MX9306215A (es) | Composicion novedosa para terapia peroral de un deterioro de la cognicion y un proceso para la fabricacion de la misma. | |
SE8503207D0 (sv) | Pharmacologically active substituted benzamides | |
RU93051352A (ru) | Замещенные производные циклогексана, способ их получения и применение соединений для лечения заболеваний | |
ES2084831T3 (es) | Nuevo procedimiento para preparar formoterol y compuestos relacionados. | |
SE8808452A (sv) | Pharmacologically active substituted benzamides | |
TW200607802A (en) | 3-piperidinylisochroman-5-ols as dopamine agonists | |
DE60016181D1 (de) | C-16 ungesätigte fp-selektive prostaglandin analoge | |
PT693070E (pt) | Pirido(2,3-b)(1,4)benzodiazepinonas como ligando do receptor m2 para o tratamento de desordens neurologicas | |
WO2003082216A3 (en) | Neuroprotectant methods, compositions, and screening methods thereof | |
WO2000047547A3 (en) | Cycloalkyl amine compounds and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |